- Home
- Results news
- Titan Biotech
- Q2 FY27 results
Titan Biotech Q2 FY27 results: net profit ₹23.40 crore vs ₹7.76 crore, revenue up 149.5%
Titan Biotech Ltd reported consolidated revenue of ₹135.63 crore and a net profit of ₹23.40 crore for Q2 FY27. Revenue rose 149.5% from the year-ago quarter, while EBITDA increased to ₹27.50 crore and the EBITDA margin expanded to 20.3%.
Key points
- Consolidated revenue was ₹135.63 crore in Q2 FY27, up ₹81.28 crore or 149.5% from Q2 FY26.
- EBITDA rose to ₹27.50 crore from ₹9.33 crore, with the margin increasing to 20.3% from 17.2%.
- Net profit was ₹23.40 crore, up ₹15.64 crore or 201.5% from Q2 FY26; basic EPS was ₹5.66.
- Against Q1 FY27, revenue rose ₹76.46 crore to ₹135.63 crore and net profit increased ₹12.54 crore to ₹23.40 crore.
- Total assets stood at ₹245.53 crore on 30 September 2026, while H1 FY27 operating cash flow was ₹12.88 crore.
How did Titan Biotech perform in Q2 FY27?
Titan Biotech reported consolidated revenue of ₹135.63 crore for Q2 FY27, up ₹81.28 crore or 149.5% from ₹54.35 crore in Q2 FY26. EBITDA rose ₹18.17 crore or 194.7% to ₹27.50 crore, while the EBITDA margin increased to 20.3% from 17.2%. Net profit increased ₹15.64 crore or 201.5% to ₹23.40 crore. Basic EPS was ₹5.66, down ₹3.74 or 39.8% from ₹9.40.
Against Q1 FY27, consolidated revenue rose ₹76.46 crore or 129.2% to ₹135.63 crore, and EBITDA increased ₹15.01 crore or 120.2% to ₹27.50 crore. The EBITDA margin fell to 20.3% from 21.1%. Net profit rose ₹12.54 crore or 115.5% to ₹23.40 crore, while basic EPS increased ₹3.03 or 115.2% to ₹5.66.
The results are consolidated. On a standalone basis, revenue was ₹135.63 crore and profit before tax was ₹6.86 crore for Q2 FY27, while standalone profit after tax was ₹20.79 crore. The board approved the unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026 on 5 November 2026.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 135.63 | 59.17 | 54.35 | +149.5% | +129.2% |
| Other income | 3.53 | 1.81 | 1.32 | +167.4% | +95.0% |
| Total expenses | 111.30 | 48.24 | 46.46 | +139.6% | +130.7% |
| EBITDA | 27.50 | 12.49 | 9.33 | +194.7% | +120.2% |
| EBITDA margin | 20.3% | 21.1% | 17.2% | +3.1 pp | −0.8 pp |
| Profit before tax | 27.86 | 12.73 | 9.22 | +202.2% | +118.9% |
| Tax | 7.07 | 3.28 | 2.36 | +199.6% | +115.5% |
| Net profit | 23.40 | 10.86 | 7.76 | +201.5% | +115.5% |
| EPS (₹) | 5.66 | 2.63 | 9.40 | −39.8% | +115.2% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Titan Biotech's costs and profit?
Total expenses rose ₹64.84 crore or 139.6% from Q2 FY26 to ₹111.30 crore. Cost of materials increased ₹42.01 crore or 153.2% to ₹69.44 crore, employee cost rose ₹10.98 crore or 148.8% to ₹18.36 crore, and other expenses increased ₹10.36 crore or 89.3% to ₹21.96 crore. Finance costs rose ₹0.26 crore to ₹0.48 crore, while depreciation increased ₹1.48 crore to ₹2.69 crore. There was no exceptional item.
Other income increased ₹2.21 crore or 167.4% from ₹1.32 crore in Q2 FY26 to ₹3.53 crore in Q2 FY27. Profit before tax rose ₹18.64 crore or 202.2% to ₹27.86 crore, while tax expense increased ₹4.71 crore or 199.6% to ₹7.07 crore. Net profit consequently rose ₹15.64 crore or 201.5% to ₹23.40 crore. The filing did not state a reason for the changes in these cost and income lines.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 69.44 | 27.43 | +42.01 | +153.2% |
| Employee cost | 18.36 | 7.38 | +10.98 | +148.8% |
| Finance costs | 0.48 | 0.22 | +0.26 | +118.2% |
| Depreciation | 2.69 | 1.21 | +1.48 | +122.3% |
| Other expenses | 21.96 | 11.60 | +10.36 | +89.3% |
| Total expenses | 111.30 | 46.46 | +64.84 | +139.6% |
| Other income | 3.53 | 1.32 | +2.21 | +167.4% |
| Tax | 7.07 | 2.36 | +4.71 | +199.6% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
At 30 September 2026, total assets were ₹245.53 crore, compared with ₹213.88 crore at 31 March 2026, while total equity rose to ₹202.84 crore from ₹181.55 crore. Borrowings increased to ₹4.21 crore from ₹3.67 crore, and cash increased to ₹4.34 crore from ₹1.48 crore. Inventories were ₹63.56 crore, trade receivables were ₹27.16 crore, and trade payables were ₹11.25 crore.
H1 FY27 operating cash flow was ₹12.88 crore, compared with ₹11.06 crore in H1 FY26. Investing cash flow was negative ₹7.72 crore versus negative ₹18.53 crore, while financing cash flow was negative ₹2.3 crore compared with ₹3.98 crore. Capital expenditure was ₹7.09 crore in H1 FY27 and ₹0.0 crore in H1 FY26.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 245.53 | 213.88 |
| Total equity | 202.84 | 181.55 |
| Borrowings | 4.21 | 3.67 |
| Cash and equivalents | 4.34 | 1.48 |
| Inventories | 63.56 | 55.77 |
| Trade receivables | 27.16 | 22.83 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | 12.88 | 11.06 |
| Cash from investing | −7.72 | −18.53 |
| Cash from financing | −2.30 | 3.98 |
| Capital expenditure | 7.09 | 0 |
Source: Company's results filing (XBRL).
How has Titan Biotech done over the last 8 quarters?
Revenue reached ₹135.63 crore in Q2 FY27, after ₹59.17 crore in Q1 FY27, while net profit rose from ₹10.86 crore to ₹23.40 crore. Over the earlier period, revenue had bottomed at ₹35.17 crore in Q4 FY25 and profit at ₹4.05 crore in the same quarter. The EBITDA margin bottomed at 12.7% in Q3 FY25 and peaked at 21.1% in Q1 FY27 before easing to 20.3%. Revenue and profit rose year on year in each of the last six quarters.
How did other Specialty Chemicals companies do?
Among 69 other Specialty Chemicals companies that filed for the quarter, the median revenue growth was 28.9%. Of these peers, 64 grew slower than Titan Biotech and 5 grew faster than the company. The peer comparison covers results available as of 6 November 2026.
| Titan Biotech revenue growth (YoY) | +149.5% |
|---|---|
| Median of 69 other Specialty Chemicals companies | +28.9% |
| Companies with slower revenue growth than Titan Biotech | 64 of 69 |
| Companies with faster revenue growth than Titan Biotech | 5 of 69 |
| Companies whose net profit rose | 53 of 63 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Titan Biotech's revenue in Q2 FY27?
Revenue from operations was ₹135.63 crore, up 149.5% from ₹54.35 crore in Q2 FY26 (consolidated).
Did Titan Biotech make a profit in Q2 FY27?
Yes. Net profit was ₹23.40 crore, against a net profit of ₹7.76 crore in Q2 FY26.
What was Titan Biotech's EPS in Q2 FY27?
Basic earnings per share were ₹5.66, against ₹9.40 in Q2 FY26.
When did Titan Biotech announce its Q2 FY27 results?
On 5 November 2026, in a filing to the BSE.
Sources
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.